Side-by-side · Research reference

Thymosin α-1vsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED8/39 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Thymosin α-1

VIP

Primary target

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Thymosin α-1

VIP

Standard dose (HBV/HCV)

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

—

Frequency

2× weekly (Mon/Thu typical)

—

Lower / starter dose

0.8 mg per injection

—

Evidence basis

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

6–12 months for chronic indications

—

Reconstitution

Sterile water for injection per vial label

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

No specific time

—

Half-life

~2 hours plasma; tissue effect days

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

04Side Effects & Safety

Parameter

Thymosin α-1

VIP

Injection site reaction

Erythema, mild discomfort

—

GI symptoms

Rare nausea

Nausea, diarrhea (VIP is endogenous GI peptide)

Fatigue

Common during initial weeks

—

Fever / flu-like

Mild interferon-like response possible

—

Autoimmune

Theoretical risk; caution in active autoimmune disease

—

Cancer risk

No signal — used as adjuvant in oncology

—

Pregnancy / OB

Avoid

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Thymosin α-1

VIP

1. Reconstitution

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

2× weekly, e.g. Monday + Thursday.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

27–31G, 4–8 mm insulin syringe.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.